EUVIMEDEUVIMED entdecken
Crossref

Synthesis and Evaluation of a Bifunctional Chelator for Thorium-227 Targeted Radiotherapy

Joshua J Woods iD, Alex Rigby, Jennifer N Wacker, Trevor Arino, Jennifer V Alvarenga Vasquez iD, Alexia Cosby, Kirsten E Martin, Rebecca J Abergel iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Joshua J Woods und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States. Hauptthemen laut MEDLINE: Chelating Agents, Thorium, Radioisotopes, Zirconium. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: NIH HHS, Basic Energy Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thorium-227 (227Th) is an α-emitting radionuclide currently under investigation for targeted alpha therapy. Available chelators used for this isotope suffer from challenging multistep syntheses. Here, we present the synthesis and preclinical evaluation of a novel bifunctional chelator, p-SCN-Bn-DOTHOPO, which contains an isothiocyanate group that is suitable for conjugation to biological molecules. This bifunctional chelator was prepared with a 26% overall yield in four steps and conjugated to the human epidermal growth factor receptor 2 targeting antibody, trastuzumab. The resulting immunoconjugate was labeled with [227Th]ThIV (pH 5.5, room temperature, 60 min) with ≥95% radiochemical yield and purity. The conjugate was also labeled with zirconium-89 (89Zr), which can be used for positron emission tomography imaging. The radiometal complexes were subsequently investigated for their biological stability. The results described here provide insight into ligand design strategies and optimization of chelators for the development of the next generation of 89Zr and 227Th radiopharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chelating AgentsThoriumRadioisotopesZirconiumImmunoconjugatesTrastuzumabHumansRadiopharmaceuticalsAnimalsErb-b2 Receptor Tyrosine KinasesIsothiocyanates

Substanzen

Chelating AgentsThoriumRadioisotopesZirconiumImmunoconjugatesTrastuzumabRadiopharmaceuticalsErb-b2 Receptor Tyrosine KinasesIsothiocyanatesThorium-227

Autor:innen und Institutionen

  • Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.
  • Department of Nuclear Engineering, University of California Berkeley, Berkeley, California 94720, United States.
  • Department of Chemistry, University of California Berkeley, Berkeley, California 94720, United States.

ORCID-Profile: Joshua J Woods, Jennifer V Alvarenga Vasquez, Rebecca J Abergel

Förderung

  • NIH HHS
  • Basic Energy Sciences

Zitieren

APA

Woods, J. J., Rigby, A., Wacker, J. N., Arino, T., Alvarenga Vasquez, J. V., Cosby, A., Martin, K. E., & Abergel, R. J. (2025). Synthesis and Evaluation of a Bifunctional Chelator for Thorium-227 Targeted Radiotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02423

Vancouver

Woods JJ, Rigby A, Wacker JN, Arino T, Alvarenga Vasquez JV, Cosby A, et al. Synthesis and Evaluation of a Bifunctional Chelator for Thorium-227 Targeted Radiotherapy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02423

BibTeX
@article{Woods2025,
  author = {Woods, Joshua J and Rigby, Alex and Wacker, Jennifer N and Arino, Trevor and Alvarenga Vasquez, Jennifer V and Cosby, Alexia and Martin, Kirsten E and Abergel, Rebecca J},
  title = {Synthesis and Evaluation of a Bifunctional Chelator for Thorium-227 Targeted Radiotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02423}
}
Kostenlos starten →